Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | BCR | P11274 | 1/20 | 0.62 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SI | P14410 | 2/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722198 | 0.89 | PDPK1 (0.77) | PDPK1ABL1BCRLOXL2ADRB2 | |
| SCHEMBL28495166 | 0.81 | PDPK1 (0.52) | PDPK1ABL1BCRLOXL2ADRB2 | |
| SCHEMBL17704291 | 0.80 | PDPK1 (0.65) | PDPK1ABL1BCRLOXL2ADRB2 | |
| SCHEMBL533558 | 0.79 | LOXL2 (0.67) | PDPK1ABL1BCRLOXL2ADRB2 | |
| SCHEMBL19219079 | 0.78 | PDPK1 (0.63) | PDPK1ABL1BCRLOXL2ADRB2 | |
| SCHEMBL10576999 | 0.78 | PDPK1 (0.63) | PDPK1ABL1BCRLOXL2ADRB2 | |
| SCHEMBL16119908 | 0.78 | PDPK1 (0.63) | PDPK1ABL1BCRLOXL2ADRB2 | |
| SCHEMBL21791658 | 0.78 | LOXL2 (0.71) | PDPK1ABL1BCRLOXL2ADRB2 | |
| SCHEMBL466426 | 0.78 | PDPK1 (0.63) | PDPK1ABL1BCRLOXL2ADRB2 | |
| SCHEMBL5147639 | 0.78 | PDPK1 (0.91) | PDPK1ABL1BCRLOXL2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4387603-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-5827869-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-27 | — | — | US | disclosed |
| US-5714496-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHERSCLEROSIS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| EP-0656897-B1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LTD (GB) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997029748-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-21 | — | — | WO | disclosed |
| US-5612359-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0702012-A1 | Substituted isoxazole sulfonamides and their use as endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0674635-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-10-04 | — | — | EP | disclosed |
| EP-0656897-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-14 | — | — | EP | disclosed |
| WO-1994014803-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994005660-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | PDPK1 1217/4885ABL1 4387/4885BCR 4143/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PDPK1 4626/4885ABL1 875/4885BCR 2872/4885 |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | HSD17B1, HSD17B13, HSD17B3 | PDPK1 1217/4885ABL1 4387/4885BCR 4143/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | PDPK1 4626/4885ABL1 875/4885BCR 2872/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | PDPK1 4626/4885ABL1 875/4885BCR 2872/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PDPK1 4626/4885ABL1 875/4885BCR 2872/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | PDPK1 4636/4885ABL1 2172/4885BCR 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.